Details
This activity encompasses two aims to be conducted at HCA Healthcare related to the COVID-19 pandemic:
Aim 1. Natural History of Disease Study: COVID-19. The objective for Aim 1 is to use HCA Healthcare data to describe clinical characteristics of COVID-19 and identify patient level factors related to disease progression and prognosis. We will examine cohorts of COVID-19 based on diagnosis codes and/or laboratory results with respect to their care and outcomes during hospitalization.
Aim 2. Near Real-Time Monitoring of Critical Drugs for the Care of Patients with COVID-19, HCA Implementation. The objective for Aim 2 is to establish the capacity to measure COVID-19 cases and COVID-19-related drug utilization data from HCA Healthcare, and to repeatedly generate and update these data and reports over time as a form of sequential monitoring.
Additional Information
Contributors
Sarah Dutcher, PhD; Grace Chai, PharmD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Candace Fuller, PhD, MPH; Sruthi Adimadhyam, MD, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Michael Nguyen, MD; Robert Ball, MD, MPH, ScM; Brian Kit, MD, MPH; Catherine Corey, MSPH; Corinne Woods, RPh, MPH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Noelle Cocoros, DSc, MPH; Katie Haffenreffer; Austin Cosgrove; Soowoo Back, MPH; Casie Horgan, MPH; Jennifer Noble; Neha Varma, MPH; Abinav Gowda; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA